Yupelri Dosage: What It Treats, How It Works, and What to Watch For

Yupelri is a prescription nebulizer medicine used for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. Its labeled regimen is once daily, but the right use of Yupelri should always be confirmed with the prescribing clinician, especially when other medicines or health conditions are involved.

Yupelri Dosage at a Glance

Yupelri is the brand name for revefenacin inhalation solution, a prescription medicine for the maintenance treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD). The official United States prescribing information describes Yupelri as a once-daily treatment administered by nebulizer. It is supplied in a single-use vial containing 175 micrograms of revefenacin in 3 mL of solution.

Yupelri dosage should not be changed, repeated, or used more often than prescribed. A clinician or pharmacist can explain how to use the prescribed nebulizer equipment, what to do if a dose is missed, and whether other inhaled medicines should be taken at a particular time. The medication should not be mixed with other drugs in the nebulizer cup unless a healthcare professional specifically advises this.

Importantly, Yupelri is a maintenance medicine, not a rescue treatment. It does not work quickly enough to manage sudden breathing difficulty. People should continue to have and understand how to use the fast-acting rescue inhaler or other emergency treatment their clinician has prescribed for acute symptoms.

What Yupelri Treats

Yupelri is approved for long-term, once-daily maintenance treatment of COPD in adults. COPD is a group of chronic lung conditions, including emphysema and chronic bronchitis, that can make it harder to move air in and out of the lungs. Symptoms may include ongoing cough, mucus production, wheezing, chest tightness, and breathlessness during everyday activity.

The medicine is intended to help support regular breathing control over time. It may be considered for people who use nebulized medicines because of personal preference, difficulty coordinating a handheld inhaler, reduced hand strength, or other practical reasons. The choice between a nebulizer and an inhaler depends on the individual’s symptoms, lung function, treatment plan, and ability to use the device correctly.

Yupelri is not labeled as a treatment for asthma and should not be used in place of an emergency bronchodilator during a COPD exacerbation. A person whose breathing is worsening despite routine treatment should contact their healthcare team promptly rather than relying on an extra dose of maintenance medication.

How Yupelri Works in the Airways

Revefenacin belongs to a class of medicines called long-acting muscarinic antagonists, also known as LAMAs or anticholinergic bronchodilators. In COPD, muscles around the airways may tighten, contributing to narrowed air passages and reduced airflow. Yupelri blocks muscarinic receptors in the airway smooth muscle, helping the muscles relax and allowing the airways to remain more open.

Because it is long acting, Yupelri is designed to provide bronchodilation across the day when used as prescribed. It does not cure COPD or reverse existing lung damage. However, regular use as part of an individualized COPD care plan may help reduce day-to-day airway narrowing and support easier breathing.

Medication is only one part of COPD care. Avoiding tobacco smoke and other lung irritants, staying up to date with recommended vaccinations, being physically active within safe limits, and participating in pulmonary rehabilitation when appropriate can all be important. A respiratory clinician can help tailor these measures to the person’s needs.

How to Use Yupelri Safely

Yupelri is inhaled through a standard jet nebulizer connected to an air compressor, using a mouthpiece. It is not intended for use in an ultrasonic nebulizer. The single-use vial is for inhalation only; it should not be swallowed, injected, or used in the eyes. Patients should follow the device instructions and the directions supplied by their pharmacist and care team.

Good nebulizer technique helps ensure that the intended amount of medicine reaches the lungs. This includes using compatible equipment, keeping the mouthpiece in place during treatment, and cleaning the nebulizer according to the manufacturer’s instructions. Poorly cleaned equipment may become contaminated and may not deliver medication effectively.

If a dose is missed, patients should ask their prescriber or pharmacist for individualized guidance. They should not take an extra dose or use two doses at once to make up for a missed treatment. If the nebulizer is damaged, unavailable, or seems not to be working properly, a pharmacist or respiratory care professional can advise on the safest next step.

Side Effects, Warnings, and Interactions

Like all medicines, Yupelri can cause side effects, although not everyone experiences them. Commonly reported side effects include cough, upper respiratory tract infection or cold-like symptoms, headache, and back pain. Discussing new or persistent symptoms with a clinician can help determine whether they may be related to the medication, COPD itself, or another health concern.

Yupelri can sometimes cause paradoxical bronchospasm, meaning breathing or wheezing suddenly becomes worse after use. This can be serious and requires stopping the medicine and using an appropriate fast-acting rescue treatment as directed by a clinician. Urgent medical assessment is needed if breathing does not improve quickly or becomes severe.

Because Yupelri has anticholinergic effects, it should be used carefully in people with narrow-angle glaucoma or urinary retention. Symptoms such as eye pain, blurred vision, seeing halos around lights, difficulty passing urine, or painful urination should be reported promptly. People with an allergy to revefenacin or any component of the product should not use it.

Patients should give their prescriber a complete list of prescription medicines, over-the-counter products, supplements, and inhalers. Using Yupelri with other anticholinergic medicines may increase side effects. The prescribing information also advises avoiding certain medicines that inhibit OATP1B1 and OATP1B3 transporters, as these may raise revefenacin exposure; a clinician or pharmacist can check for relevant interactions.

When to Seek Medical Care

Emergency medical care is appropriate for severe or rapidly worsening shortness of breath, trouble speaking because of breathlessness, blue or gray lips or fingertips, confusion, fainting, chest pain, or swelling of the face, tongue, or throat. These symptoms may indicate a serious breathing problem, a severe allergic reaction, or another urgent condition.

A clinician should be contacted promptly if COPD symptoms are becoming more frequent, a rescue inhaler is needed more often than usual, mucus changes noticeably in color or amount, fever develops, or everyday activities become more difficult because of breathing. These changes can signal a COPD flare-up or infection and may require a treatment review.

People should also seek medical advice if they develop new eye symptoms, urinary difficulty, persistent side effects, or uncertainty about their Yupelri dosage or nebulizer technique. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals evaluate and treat respiratory conditions for international patients, with care plans based on individual clinical needs.

Questions to Discuss With the Prescribing Clinician

Before starting Yupelri, patients may find it helpful to ask why a nebulized LAMA is being recommended, how it fits with their current inhalers, and which medicine should be used for sudden symptoms. They can also ask for a demonstration of nebulizer assembly and cleaning, since technique can affect treatment delivery.

It is important to review other health conditions, especially glaucoma, urinary retention, enlarged prostate, kidney problems, and a history of medication allergies. A clinician should also know about all inhaled treatments, including other LAMA medicines, because overlapping anticholinergic effects may increase the risk of side effects.

Regular follow-up allows the care team to assess symptoms, rescue medicine use, device technique, side effects, and the broader COPD plan. Patients should bring their medication list and, when practical, their nebulizer equipment to appointments so that any questions can be addressed clearly and safely.

Frequently asked questions

What is the usual Yupelri dosage?

The official prescribing information describes Yupelri as a once-daily nebulized treatment, supplied as a single-use vial containing 175 micrograms of revefenacin in 3 mL. Individual questions about timing, missed doses, or whether the medicine is suitable for a particular person should be directed to the prescribing clinician or pharmacist.

Can Yupelri be used for sudden shortness of breath?

No. Yupelri is a maintenance bronchodilator and is not intended to treat sudden breathing problems or an acute COPD flare-up. Patients should use the fast-acting rescue medicine included in their care plan and seek urgent help for severe or worsening symptoms.

Is Yupelri used for asthma?

Yupelri is approved for maintenance treatment of COPD in adults. It is not labeled as an asthma treatment. Anyone with asthma symptoms should speak with a clinician about medicines specifically recommended for their condition.

What are the most common Yupelri side effects?

Reported common side effects include cough, upper respiratory tract infection or cold-like symptoms, headache, and back pain. Patients should tell a healthcare professional about side effects that are bothersome, persistent, or concerning.

Can Yupelri be taken with other inhalers?

Some people use Yupelri alongside other COPD medicines, but the combination should be decided by a clinician. In particular, other anticholinergic medicines may increase the chance of side effects. A pharmacist can review all inhalers and medicines for possible duplication or interactions.

Who should use caution with Yupelri?

People with narrow-angle glaucoma or urinary retention should discuss Yupelri carefully with their clinician because its anticholinergic effects can worsen these conditions. Those with a known allergy to revefenacin or product ingredients should not use it. New eye pain, blurred vision, or trouble urinating should be reported promptly.

References

• U.S. Food and Drug Administration
• Yupelri Prescribing Information
• Global Initiative for Chronic Obstructive Lung Disease
• American Lung Association

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.